6979 results for
Refine Your Search
Ushering In a New Era of Pediatric Blood Cancer Treatment and Care
We caught up with Gwen Nichols, MD, Chief Medical Officer at The Leukemia & Lymphoma Society (LLS), to share the progress we’re making to bring cures …
Paul
My husband's story began in July 2018, when he suddenly became ill. I rushed him to the ER. The shocking diagnosis, multiple myeloma. Three weeks prio…
Celebrating Survivorship: Natalie Abreu-Horne
I was diagnosed with Acute Myeloid Leukemia (with a FLT3 mutation), at age 46, on April 24, 2018. I had no idea I was as sick as I was until I was in …
Natalie
I was diagnosed with acute myeloid leukemia (with a FLT3 mutation), at age 46, on April 24, 2018. I had no idea I was as sick as I was until I was in …
Verastem Oncology Announces Closing of Duvelisib Sale to Secura Bio
BOSTON - Sep. 30, 2020 - Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medici…
Trish
After being diagnosed with indolent follicular non-Hodgkin lymphoma (NHL) in 1999, I set off on a course of watch- and-wait for two years. This was fo…
Affimed Doses First Patient in Phase 1 Clinical Trial of Natural Killer Cells in Combination with AFM13
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their i…
Jackson
Jackson was diagnosed on December 31, 2016 age eight with Philadelphia positive acute leukemia. Doctor's said he wouldn't live long and transferred hi…
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T …
X4 Pharmaceuticals Announces FDA Fast Track Designation Granted to Mavorixafor for the Treatment of WHIM Syndrome
BOSTON, Oct. 08, 2020 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resul…
All About "The 100 Days Agenda: A Patient-First Blueprint"
The whole world can change in 100 days. We learned that lesson painfully in early 2020. But what if something positive could happen just as quickly?
Atención Médica Para Personas Indocumentadas
En la mayoría de los estados, los inmigrantes indocumentados no reúnen los requisitos para inscribirse en Medicare, Medicaid ni en el Programa de Segu…
Education Resources
Understanding Myeloma
Topics Covered We invite you to learn more about: Determining treatment for your myeloma Newer therapies to treat myeloma Managing side effects …
OncoPep Strengthens Pipeline with Addition of Multi-Tumor Antigen Adoptive T Cell Therapy
BOSTON – October 15, 2020 – OncoPep, Inc. today announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the developm…
News Release
Amanda
The word “warrior” seems too tame to describe Amanda Monteiro, a volunteer with The Leukemia and Lymphoma Society (LLS). She’s fueled by her desire to…
Kamisa
August 9, 2019, what should’ve been the happiest day of my life turned out to be the worst. I gave birth to my beautiful son, only to find out I had s…
William
Hi, my name is William Yank and I am a 23-year-old, three-time leukemia survivor from Indiana. My story begins at the end of my junior year of college…
Study in Nature Medicine Shows Superior Outcomes for Patients in LLS's Paradigm-Shifting Beat AML Clinical Trial
Bringing Precision Medicine to AML patients: LLS’S Beat AML® Master Clinical Trial
Brianna
My name is Brianna Ciambra I live in New York and this is my story. When I was eleven, I was diagnosed with acute lymphoblastic leukemia. I went throu…
HCL2025 guidelines
The HCLF and LLS joining forces to expanding research in Hairy Cell Leukemia to better characterize its biology, develop new therapies, and optimize o…
Five-Year-Old Cancer Survivor Gets One-of-a-Kind “Curbside Pickup" Experience
Vaughn was a healthy baby until he was diagnosed at 11 months old with high-risk infantile leukemia. He was placed on an aggressive experimental infan…
Research Shows Impact of Caregiver Experience on Families
Important findings of research conducted by the University of Florida's Drs. Carma Bylund and Carla Fisher in collaboration with LLS and The LLS Commu…
November 2020- Patient & Caregiver Virtual Education Programs
Surviving & Thriving with Childhood Blood CancerA Virtual Education Program (Red River)November 5, 20206:30PM - 8:00PM (CT)Taking Care of Your Mental …
News Release
NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia
GAITHERSBURG, MD - October 27, 2020 - NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunother…
Sanofi offers to acquire Kiadis for €308 million
Paris, France and Amsterdam, The Netherlands, 2 November 2020 – Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a…